Inactive Instrument

Highlights Beigene Ltd Hong Kong S.E.

Equities

End-of-day quote Hong Kong S.E. Other stock markets
- ^HKD	-

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	CI
US FDA approves BeiGene's esophageal cancer therapy	Mar. 14	RE
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership	Mar. 13	MT
BeiGene Shares Rise on First Dosing of Brukinsa	Mar. 13	DJ
BeiGene Gets FDA's Accelerated Approval for Follicular Lymphoma Treatment	Mar. 07	MT
BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma	Mar. 07	CI
US FDA approves expanded use of BeiGene's blood cancer drug	Mar. 07	RE
BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024	Mar. 06	CI
BeiGene's Pi Health Units to Merge	Mar. 06	MT
BeiGene Says FDA Accepts License Application For Tevimbra For Gastric Cancers	Feb. 27	MT
BeiGene's Q4 2023 Net Loss Narrows as Revenue Increases; Misses Estimates	Feb. 26	MT
BeiGene's Q4 Net Loss Narrows, Revenue Rises	Feb. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Beigene Ltd Hong Kong S.E.

Equities

Highlights

Filters